Methods, devices, and systems for adjusting laboratory HbA1c values
Inventors
Xu, Yongjin • Dunn, Timothy C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12633384-B2
Publication Date
2026-05-19
Expiration Date
Abstract
A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.
Core Innovation
The invention provides personalized treatment by using a remote device to receive first data indicative of an analyte level of a subject during a first time period and retrieving a first glycated hemoglobin level for the subject associated with the first time period. The remote device calculates a first personal apparent glycation ratio for the first time period using the received first data and the retrieved glycated hemoglobin level.
The remote device compares the calculated first personal apparent glycation ratio to a representative apparent glycation ratio obtained from one or more members of a demographic cohort, where the subject belongs to the demographic cohort. The demographic cohort is defined based on at least one of age, gender, or race, and the comparison is used to determine whether the calculated personal ratio deviates from the representative ratio by a threshold amount.
In response to the deviation determination, the remote device generates a recommendation for personalized insulin therapy that includes at least one of adjusting a personalized clinical limit for insulin therapy or recommending a change in the insulin therapy. The recommendation is then used to cause administration of an insulin dosage according to the recommendation by an insulin pump system of the subject.
Claims Coverage
The independent claims are clm-00001, clm-00021, and clm-00023. Across these claims, the inventive features focus on calculating a personal apparent glycation ratio from subject analyte data and retrieved glycated hemoglobin, comparing it to a representative cohort ratio defined by demographic criteria, and generating a threshold-triggered insulin-therapy recommendation that drives insulin dosage administration by an insulin pump system.
Personal apparent glycation ratio from analyte and glycated hemoglobin
receiving first data indicative of an analyte level of a subject during a first time period; retrieving a first glycated hemoglobin level for the subject associated with the first time period; and calculating a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level
Demographic-cohort representative ratio comparison
comparing the calculated first personal apparent glycation ratio to a representative apparent glycation ratio obtained from one or more members of a demographic cohort, wherein the subject belongs to the demographic cohort, and wherein the demographic cohort is defined based on at least one of age, gender, or race
Threshold-deviation conditioned insulin therapy recommendation
generating a recommendation based on the comparison, wherein the recommendation includes at least one of: (i) adjusting a personalized clinical limit for insulin therapy of the subject or (ii) recommending a change in the insulin therapy, wherein the recommendation is provided in response to a determination that the calculated first personal apparent glycation ratio deviates from the representative apparent glycation ratio by a threshold amount
Insulin pump administration according to recommendation
causing an administration of an insulin dosage according to the recommendation by an insulin pump system of the subject
Computer system implementation of personalized treatment
a computer system comprising one or more processors and one or more hardware storage devices storing instructions executable by the one or more processors to: receive first data indicative of an analyte level of a subject during a first time period; retrieve a first glycated hemoglobin level for the subject associated with the first time period; calculate a first personal apparent glycation ratio; compare it to a representative apparent glycation ratio obtained from one or more members of a demographic cohort defined based on at least one of age, gender, or race; generate a recommendation as defined by the threshold-deviation condition; and cause an administration of an insulin dosage according to the recommendation by an insulin pump system of the subject
Across the independent claims, the method/system is centered on computing a personal apparent glycation ratio from analyte level data and retrieved glycated hemoglobin, comparing that ratio to a demographic-cohort representative ratio, and producing a threshold-triggered insulin-therapy recommendation that is then used to cause insulin dosage administration by an insulin pump system.
Stated Advantages
Improved correlation/variance reduction of cHbA1c versus measured HbA1c [as described in the document summary content provided]
Quantified effects of RBC lifespan and demographic factors on AGR and HbA1c-glucose relationships [as described in the document summary content provided]
Documented Applications
Personalized diabetes management by adjusting insulin therapy based on deviation between a personal apparent glycation ratio and a representative apparent glycation ratio derived from a demographic cohort [as described in the document summary content provided].
Interested in licensing this patent?